The Minnesota Star Tribune’s Post

Check out my blog post on How Crypta Revolutionizes Early Safety Signal Detection in Emerging Markets! https://wix.to/GhmMvND #newblogpost

Every year, more top-selling pharmaceuticals require cold chain packaging and related services. Many of today’s most critical life sciences products rely on advanced cold chain packaging to reach patients in optimal condition, ensuring the health and well-being of millions of people around the world. This recent article with Ranjeet Banerjee, CEO of Cold Chain Technologies, discusses attractive trends and opportunities in the cold chain packaging sector.

Every year, more top-selling pharmaceuticals require cold chain packaging and related services. Many of today’s most critical life sciences products rely on advanced cold chain packaging to reach patients in optimal condition, ensuring the health and well-being of millions of people around the world. This recent article with Ranjeet Banerjee, CEO of Cold Chain Technologies, discusses attractive trends and opportunities in the cold chain packaging sector.

Rising Varied Investment Products, Regulatory Activity Drive Demand in Investment Funds

It's taken me a while but I've written my first piece for Doceo Group. The pain relief market is projected to expand by £15 billion in the next two years. I've looked into the reasons behind this, and explored how #InvestmentTrusts are supporting pharmaceutical companies in meeting growing demand. #painrelief #drugdiscovery #drugdevelopment

Rising Varied Investment Products, Regulatory Activity Drive Demand in Investment Funds

After completing objective, I rise my expected price at Roche to 250€, my expected portfolios value also rise a little #Investment #Value

Increasing pricing pressures, uncertain geopolitical environment, changing regulatory landscape, and acceleration of GenAI adoption…Discover how industry leaders are navigating the year of transformation in Deloitte's Global Life Sciences Sector Outlook. https://lnkd.in/dbdmZviD

I like the optimistic outlook! Question is: how far ahead is the US? 👀 — When can we expect some positive momentum to hit SMES in the Nordics? 📈 Sure would love to see some of that abundant large-pharma cash coming this way in 2024! 💰💰💰 (Not to mention the notion of a successful life science-IPO in Sweden again, that would be a sight for sore eyes!) 🥹 Interesting read from our friends at Back Bay Life Science Advisors nevertheless! 🤓 ”It will be interesting to see how deal making in the healthcare sector will perform in 2024. Potential interest rate cuts, large-pharma sitting on record high cash balances, approaching patent cliffs for blockbuster drugs, and the continuous growing list of companies in the IPO queue all provide reasons to be optimisitic.” #lifescience #nordics #momentum #ipo BioStock - Connecting Innovation and Capital

Rising Varied Investment Products, Regulatory Activity Drive Demand in Investment Funds